Fermenta Biotech received FSSAI approval for VITADEE Green®, enabling domestic production of plant-based Vitamin D3 for supplements, nutraceuticals, and fortified foods.
Fermenta Biotech Limited (FBL) has secured approval from the Food Safety and Standards Authority of India (FSSAI) for its plant-source Vitamin D3, also known as Cholecalciferol. This significant regulatory clearance allows FBL to manufacture and sell this product in India for use in health supplements, nutraceuticals, and food items. The product, branded as VITADEE Green®, is developed and manufactured entirely within India, aligning with the "Make in India" initiative.
Traditional Vitamin D3 is primarily derived from lanolin, which comes from sheep's wool, making it unsuitable for vegans and vegetarians. Fermenta's plant-source Vitamin D3, derived from lichen, offers a crucial alternative for individuals with dietary restrictions, including those with religious considerations. This innovation addresses a significant gap in the Indian nutritional market and caters to the increasing demand for plant-based and sustainable health supplements. The approval positions Fermenta Biotech to enter the high-growth vegan food fortification and supplement market.
As a leading global manufacturer of Vitamin D3, this FSSAI approval strengthens Fermenta Biotech's product portfolio and expands its market reach. The ability to domestically produce and market a plant-based Vitamin D3 enhances India's self-reliance in nutrition solutions and supports local production. This move also highlights FBL's commitment to innovation and sustainable solutions within the nutraceutical sector. The company's proprietary manufacturing process for plant-based Vitamin D3 has also received an Indian patent, reinforcing its intellectual property and leadership in sustainable Vitamin D3 solutions.
The global Vitamin D market continues to grow, driven by increasing health awareness and the recognized benefits of Vitamin D3 for bone health, immune function, and overall well-being. Fermenta's plant-based offering provides a competitive advantage by tapping into the expanding vegan and vegetarian consumer base, which represents a substantial portion of the Indian population. This strategic diversification into high-margin vegan ingredients could lead to increased business-to-business partnerships with fast-moving consumer goods (FMCG) companies focused on fortified "clean-label" foods. The approval also de-risks the company's valuations and expands its addressable market in a health-conscious environment.
Impact on Products and Chemical Commodities:
The FSSAI approval for Fermenta Biotech’s plant-based Vitamin D3 is expected to accelerate the adoption of vegan and sustainable nutraceutical ingredients across India’s health supplement and food fortification sectors. Demand for plant-derived Vitamin D3 (Cholecalciferol) is likely to increase as manufacturers of dietary supplements, fortified dairy alternatives, beverages, cereals, and functional foods shift toward clean-label and vegan formulations. This development may gradually reduce dependence on lanolin-derived Vitamin D3 in niche applications, although conventional Vitamin D3 will continue to dominate due to its established supply chain and lower production cost. For chemical commodities tracked by ChemAnalyst, the immediate price impact is expected to be limited, as Vitamin D3 represents a specialized, value-added nutraceutical ingredient rather than a bulk chemical. However, sustained growth in plant-based nutrition could strengthen demand and support stable-to-firm prices for specialty nutraceutical ingredients, while creating modest pricing pressure on traditional lanolin-derived Vitamin D3 over the longer term as competition increases.
